Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P04141
UPID:
CSF2_HUMAN
Alternative names:
Colony-stimulating factor; Molgramostin; Sargramostim
Alternative UPACC:
P04141; Q14CE8; Q2VPI8; Q8NFI6
Background:
Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as Colony-stimulating factor, Molgramostin, and Sargramostim, is a pivotal cytokine. It plays a crucial role in the growth and differentiation of hematopoietic precursor cells into various lineages, including granulocytes, macrophages, eosinophils, and erythrocytes.
Therapeutic significance:
Understanding the role of Granulocyte-macrophage colony-stimulating factor could open doors to potential therapeutic strategies. Its ability to influence the hematopoietic system suggests its utility in treating conditions related to blood and immune cells.